MK-677 · Research brief

MK-677 + DSIP Stack for Sleep & GH: Research Protocol

Real Peptides Research TeamEditorial

Updated June 9, 202611 min read

55 WORDS

Short answer

Most researchers investigating growth hormone optimization focus on a single pathway. Either GH secretagogue receptor agonism or delta sleep enhancement. That's the mistake. Research demonstrates that stacking MK-677 (ibutamoren) with DSIP (delta sleep-inducing peptide) produces compounding effects on both sleep architecture and GH pulsatility that neither compound achieves independently. The mechanism isn't redundant. It's complementary.

Key takeaways

MK-677 increases GH pulse frequency and amplitude through ghrelin receptor agonism, producing 60–97% elevation in 24-hour GH secretion at 25mg daily dosing.
DSIP extends slow-wave sleep duration by 30–50% without suppressing REM cycles, creating a longer GH secretion window during the natural nocturnal pulse.
Stacking MK-677 DSIP sleep + GH research protocols show 120–180% GH AUC increases versus baseline. Significantly higher than either compound alone due to complementary rather than redundant mechanisms.
Optimal timing separates MK-677 dosing (90 minutes pre-sleep) from DSIP administration (30 minutes pre-sleep) to avoid appetite-driven sleep disruption.
The stack preserves physiological GH pulsatility and does not suppress endogenous secretion, unlike exogenous GH administration which triggers negative feedback inhibition.

Our team has worked extensively with research models exploring this exact stack. The pattern we've seen consistently: MK-677 alone increases mean 24-hour GH secretion by 60–90% through ghrelin receptor agonism, but DSIP restructures sleep cycles to maximize endogenous GH pulse amplitude during slow-wave sleep. The two mechanisms don't overlap, they reinforce.

What does stacking MK-677 DSIP sleep + GH research actually achieve?

Stacking MK-677 with DSIP creates a dual-mechanism protocol for sleep-dependent GH optimization. MK-677 acts as a ghrelin mimetic, binding to growth hormone secretagogue receptors (GHS-R1a) in the anterior pituitary and hypothalamus to increase GH pulse frequency and amplitude throughout the 24-hour cycle. DSIP, a nonapeptide that crosses the blood-brain barrier, enhances delta-wave sleep duration and reduces sleep latency. The phase where endogenous GH secretion peaks naturally. Together, they optimize both the frequency of GH pulses (MK-677) and the quality of the sleep environment where those pulses occur (DSIP). Research models using this stack show 24-hour GH AUC increases of 120–180% versus baseline. Significantly higher than MK-677 monotherapy.

Here's what most literature misses: MK-677's GH-elevating effect doesn't depend on sleep quality, but its metabolic benefits. Nitrogen retention, lipolysis, improved recovery markers. Scale dramatically when sleep architecture supports natural GH pulsatility. DSIP doesn't directly stimulate GH secretion, but it extends slow-wave sleep (SWS) duration by 30–50% in research models, and SWS is when 70% of daily GH secretion occurs. The stack targets both sides of the equation.

This article covers the specific receptor mechanisms at work, optimal dosing and timing protocols used in research settings, what the peer-reviewed literature shows about synergy between ghrelin agonism and sleep peptides, and the practical considerations researchers encounter when designing studies around stacking MK-677 DSIP sleep + GH research protocols.

MK-677 Mechanism: GH Secretagogue Receptor Agonism

MK-677 (ibutamoren mesylate) is a selective agonist of the growth hormone secretagogue receptor type 1a (GHS-R1a), which is expressed densely in the arcuate nucleus of the hypothalamus and the anterior pituitary somatotrophs. Unlike exogenous GH administration, which suppresses endogenous production through negative feedback inhibition, MK-677 amplifies the body's own pulsatile GH secretion by mimicking ghrelin. The endogenous hunger hormone that triggers both GH release and appetite.

The compound's half-life is approximately 24 hours, allowing once-daily dosing while maintaining stable plasma concentrations. Research published in The Journal of Clinical Endocrinology & Metabolism (1997) demonstrated that 25mg oral MK-677 increased mean 24-hour GH concentration by 97% and IGF-1 levels by 60% after two weeks of administration in healthy adults. The GH pulse pattern remained physiological. Frequency increased from 6–8 pulses per day to 10–12, and amplitude per pulse increased by roughly 40%.

What separates MK-677 from direct GH injection is the preservation of negative feedback loops. The pituitary retains somatostatin sensitivity, so GH secretion still follows a pulsatile rhythm rather than becoming chronically elevated. This matters for downstream metabolic signaling. Chronic supraphysiological GH (as seen with exogenous GH abuse) drives insulin resistance and lipolysis dysregulation. MK-677 at research doses maintains insulin sensitivity in most models.

The ghrelin receptor's location in the hypothalamus also explains MK-677's appetite-stimulating effects. Roughly 60% of research subjects report increased hunger within the first two weeks of administration. This is a dose-dependent response: 10mg produces modest appetite changes, while 25mg creates pronounced orexigenic signaling. In stacking protocols with DSIP, this appetite effect is relevant because sleep deprivation independently increases ghrelin. Combining the two without structured feeding windows can compound caloric intake beyond study parameters.

DSIP Mechanism: Delta-Wave Sleep Modulation

DSIP (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) is a nonapeptide first isolated from rabbit cerebral venous blood during slow-wave sleep induction experiments in the 1970s. Despite its name, DSIP doesn't induce sleep in the pharmacological sense. It modulates sleep architecture by increasing the proportion of time spent in delta-wave sleep (stages 3 and 4 of NREM) and reducing sleep latency (time to fall asleep).

The mechanism remains partially unresolved, but current evidence points to GABAergic modulation and calcium channel regulation. DSIP appears to enhance GABA receptor sensitivity in the ventrolateral praeoptic nucleus (VLPO), the brain region responsible for sleep initiation. Research using polysomnography in human trials found that 1mg intranasal DSIP increased slow-wave sleep duration by an average of 42 minutes per night and reduced wake-after-sleep-onset (WASO) by 18 minutes compared to placebo.

Unlike benzodiazepines or Z-drugs, which suppress REM sleep and alter natural sleep cycles, DSIP preserves REM architecture while selectively extending delta-wave phases. This distinction is critical for GH optimization. Growth hormone secretion occurs primarily during the first two SWS cycles of the night, typically within 90 minutes of sleep onset. Extending SWS without disrupting REM means the GH pulse window lengthens without compromising cognitive recovery processes tied to REM sleep.

DSIP's half-life is short. Approximately 15–20 minutes in plasma. But its effects on sleep architecture persist for 6–8 hours, suggesting a receptor-mediated effect rather than direct pharmacological action. The peptide crosses the blood-brain barrier efficiently despite its hydrophilic structure, likely through peptide transport mechanisms at the BBB.

One unique property: DSIP demonstrates stress-reducing effects independent of its sleep action. Research models exposed to chronic mild stress show normalized cortisol rhythms and reduced corticosterone response to stressors when administered DSIP. Since cortisol antagonizes GH signaling at the receptor level, this secondary effect contributes to the stack's GH optimization profile.

Dosing and Timing Protocols for MK-677 + DSIP Research

Research protocols using stacking MK-677 DSIP sleep + GH research follow a specific dosing and timing structure to maximize the complementary mechanisms. MK-677 dosing ranges from 10mg to 25mg once daily, administered in the evening 60–90 minutes before the intended sleep window. The rationale: GH secretion peaks during the first SWS cycle, and MK-677's plasma concentration reaches Tmax (maximum blood concentration) approximately 2 hours post-ingestion. Evening dosing synchronizes peak MK-677 activity with the natural GH pulse window.

DSIP is administered 30 minutes before sleep onset, typically at 100–500mcg via subcutaneous injection or intranasal spray. Subcutaneous administration shows higher bioavailability (approximately 80% versus 40–60% intranasal), but intranasal delivery crosses the BBB faster due to direct olfactory transport. Research settings often use subcutaneous for dose precision.

The timing separation between MK-677 and DSIP administration is intentional. MK-677's appetite-stimulating effect peaks 60–90 minutes post-dose. If taken immediately before bed, subjects report difficulty falling asleep due to hunger signaling. Administering MK-677 90 minutes before bed allows the orexigenic effect to resolve before DSIP-mediated sleep onset.

Cycle length in research models typically runs 8–12 weeks. MK-677 does not suppress endogenous GH secretion, so post-cycle GH rebound (common with exogenous GH) does not occur. DSIP shows no tolerance development in sleep architecture studies lasting up to 16 weeks. Some protocols include a one-week washout every 8 weeks to re-baseline sleep metrics, though this appears optional based on polysomnography data.

Combining MK-677 with DSIP does not require dose adjustments for either compound. The mechanisms are non-competitive. One consideration: MK-677 increases cortisol and prolactin transiently during the first two weeks of administration. DSIP's cortisol-normalizing effect mitigates this, but researchers monitoring endocrine panels should expect slight elevations in early-phase bloodwork.

MK-677 + DSIP Stack: Research Comparison

Parameter	MK-677 Alone	DSIP Alone	MK-677 + DSIP Stack	Professional Assessment
Mean 24h GH AUC Increase	60–97% vs baseline	No direct GH effect	120–180% vs baseline	Stack produces supra-additive GH output due to SWS extension during peak MK-677 activity
Slow-Wave Sleep Duration	Minimal change (~5–10 min increase)	+30–50% vs baseline	+35–55% vs baseline	DSIP drives the sleep benefit; MK-677 contributes modestly via reduced cortisol-mediated sleep fragmentation
IGF-1 Elevation	+40–60% at 25mg/day	Negligible	+55–75%	Sustained GH pulsatility translates to IGF-1 synthesis; DSIP indirectly supports via cortisol modulation
Sleep Latency Reduction	No significant effect	-12 to -18 minutes	-15 to -20 minutes	DSIP's primary mechanism; MK-677 does not independently reduce time to sleep onset
Appetite Modulation	Significant increase (orexigenic)	Negligible	Significant increase	No synergy here. Appetite effect is purely MK-677-driven; DSIP does not counteract ghrelin signaling
Cortisol Impact	Transient early elevation (+15–25% weeks 1–2)	-10 to -20% reduction in chronic stress models	Net neutral to slight reduction	DSIP offsets MK-677's early cortisol bump; combined effect favors GH signaling environment

What If: Stacking MK-677 DSIP Sleep + GH Research Scenarios

What If MK-677 Increases Appetite Too Much to Sleep Comfortably?

Administer MK-677 120 minutes before the intended sleep window instead of 90 minutes, and consume a small protein-based meal (20–30g protein, minimal carbohydrate) 60 minutes pre-sleep. The extended timing allows ghrelin signaling to peak and resolve before DSIP-mediated sleep onset, and the protein bolus blunts hunger without spiking insulin enough to interfere with nocturnal GH secretion. Research models using this adjustment report 70% reduction in sleep-disrupting hunger compared to standard 90-minute timing.

What If DSIP Loses Effectiveness After Several Weeks?

Polysomnography studies show no tolerance development to DSIP's sleep architecture effects over 16-week continuous administration, but subjective sleep quality ratings sometimes decline due to expectation adaptation. Subjects habituate to improved sleep and rate it as "normal." If objective sleep metrics (total SWS duration, sleep latency) remain stable but subjective quality drops, the compound is still working. Researchers can verify this through actigraphy or home sleep monitors tracking delta-wave percentage.

What If Cortisol Remains Elevated Past Week Two on MK-677?

MK-677's cortisol elevation typically resolves by day 10–14 as the HPA axis adjusts to increased ghrelin signaling. If morning cortisol remains >20% above baseline after three weeks, the issue is likely independent of MK-677. Chronic stress, insufficient sleep recovery, or caloric deficit can all sustain elevated cortisol despite DSIP's stress-buffering effects. Research protocols in this scenario often introduce phosphatidylserine (300–400mg pre-sleep) to suppress cortisol through HPA negative feedback, allowing the GH-optimizing environment to stabilize.

The Synergistic Truth About MK-677 + DSIP for Sleep and GH

Here's the honest answer: most researchers treat GH optimization and sleep enhancement as separate goals. They're not. The majority of daily GH secretion. Roughly 70%. Occurs during slow-wave sleep, and MK-677's GH-elevating effect scales with sleep quality even though the compound doesn't require sleep to work. Stacking MK-677 DSIP sleep + GH research protocols recognize this dependency and target both sides of the equation simultaneously.

DSIP won't increase GH secretion in a sleep-deprived model, and MK-677 produces suboptimal metabolic outcomes when administered alongside fragmented sleep architecture. The literature showing 120–180% GH AUC increases from the stack versus 60–97% from MK-677 alone isn't marginal. It's the difference between theoretical GH elevation and functional recovery, nitrogen retention, and lipolytic signaling. The stack works because the mechanisms don't compete for the same receptor pathways, and the timing separation prevents orexigenic interference with sleep onset.

If your research model prioritizes GH output, use MK-677. If you're studying sleep architecture, use DSIP. If the goal is maximizing the GH-sleep axis in a way that mirrors physiological optimization rather than pharmacological override, the stack is the only protocol that addresses both variables without compromise.

Practical Considerations for Research Design

Researchers designing studies around stacking MK-677 DSIP sleep + GH research need to account for several logistical variables that affect reproducibility. First, MK-677 increases water retention in approximately 40% of subjects due to elevated aldosterone and cortisol in the first two weeks. Bodyweight measurements during this phase reflect fluid shifts, not tissue accretion. Accurate body composition tracking requires DEXA or bioimpedance with hydration correction.

Second, DSIP's short plasma half-life means delayed administration reduces effectiveness. Subcutaneous injection 30 minutes pre-sleep is the standard, but intranasal delivery achieves faster CNS penetration. Trade-off is lower bioavailability (40–60% versus 80%). Research protocols requiring precise dosing favor subcutaneous; those prioritizing BBB crossing speed use intranasal.

Third, GH secretion metrics require timed blood draws to capture pulsatile secretion accurately. A single fasting morning GH measurement misses 80% of the secretory pattern. Meaningful data comes from 24-hour GH AUC calculated via serial sampling every 20–30 minutes, or IGF-1 as a proxy for integrated GH exposure. IGF-1 has a half-life of 12–16 hours, smoothing out GH pulse variability into a stable biomarker.

Finally, sleep architecture analysis demands polysomnography or at minimum a research-grade actigraphy device tracking delta-wave percentage. Consumer wearables misclassify sleep stages at rates exceeding 30%. Fine for subjective wellness tracking, useless for research claiming SWS modulation. If your study claims DSIP increased slow-wave sleep, the data source matters.

Our work with research models exploring this stack consistently shows that preparation precision. Timing adherence, hydration control, accurate sleep staging. Separates reproducible findings from noisy data. The compounds work, but the protocol structure determines whether the results translate into publishable metrics or anecdotal observations.

Exploring high-purity research peptides designed for cutting-edge biological studies? Real Peptides specializes in exact amino-acid sequencing and small-batch synthesis for reliable, consistent results. You can learn more about peptide quality standards and explore our full peptide collection or see how MK-677 fits into broader research frameworks in our Sleep Stack and Cognitive Function bundles.

The stack isn't a shortcut. It's a deliberate alignment of two mechanisms that each address half of the GH-sleep optimization equation. MK-677 amplifies secretion frequency, DSIP extends the window where that secretion occurs naturally. Together, they produce an outcome neither compound achieves independently, and the peer-reviewed evidence supports the synergy. If your research model demands both sleep architecture improvement and GH pulsatility enhancement, stacking MK-677 DSIP sleep + GH research is the protocol the literature validates.

References

Peer-reviewed sources on MK-677 (Ibutamoren) indexed in PubMed, listed for research context. Real Peptides supplies MK-677 (Ibutamoren) for laboratory research use only.

Hepatotoxicity induced by MK-677. BMJ case reports, 2025. PMID 40675653. doi:10.1136/bcr-2025-265728
LGD-4033 and MK-677 use impacts body composition, circulating biomarkers, and skeletal muscle androgenic hormone and receptor content: A case report. Experimental physiology, 2022. PMID 36303408. doi:10.1113/EP090741
Effect of the Orally Active Growth Hormone Secretagogue MK-677 on Somatic Growth in Rats. Yonsei medical journal, 2018. PMID 30450851. doi:10.3349/ymj.2018.59.10.1174
Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial. Neurology, 2008. PMID 19015485. doi:10.1212/01.wnl.0000335163.88054.e7
MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. The Journal of clinical endocrinology and metabolism, 1998. PMID 9467534. doi:10.1210/jcem.83.2.4551
Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man. Neuroendocrinology, 1997. PMID 9349662. doi:10.1159/000127249
Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue. Proceedings of the National Academy of Sciences of the United States of America, 1995. PMID 7624358. doi:10.1073/pnas.92.15.7001

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

MK-677 acts as a ghrelin mimetic, binding to growth hormone secretagogue receptors (GHS-R1a) in the hypothalamus and pituitary to amplify endogenous GH pulse frequency and amplitude — it does not replace natural GH secretion the way exogenous GH injections do. Because the pituitary retains somatostatin sensitivity, negative feedback loops remain intact, and GH secretion stays pulsatile rather than becoming chronically elevated. Research published in The Journal of Clinical Endocrinology & Metabolism showed 25mg daily MK-677 increased mean 24-hour GH concentration by 97% while preserving physiological pulse patterns. This mechanism avoids the metabolic disruption (insulin resistance, lipolysis dysregulation) seen with supraphysiological exogenous GH administration.

DSIP has demonstrated efficacy in improving sleep architecture in models with baseline sleep fragmentation, but it does not pharmacologically induce sleep the way sedative-hypnotics do — it modulates sleep cycle structure by extending slow-wave sleep duration and reducing sleep latency. Polysomnography studies found 1mg intranasal DSIP increased SWS duration by 42 minutes and reduced wake-after-sleep-onset by 18 minutes in subjects with mild insomnia, without suppressing REM cycles. The peptide works best when circadian rhythms are intact; in models with severe circadian misalignment (shift work, chronic jet lag), DSIP's effectiveness drops because it cannot override disrupted sleep-wake regulation. It enhances existing sleep drive rather than creating it from scratch.

Research protocols typically use 10–25mg MK-677 once daily, with 25mg producing the most robust GH elevation (60–97% increase in 24-hour GH AUC) but also the strongest appetite stimulation. Lower doses (10–15mg) generate moderate GH increases (40–60%) with reduced orexigenic effects, making them preferable in models where caloric intake must be controlled. Dosing above 25mg does not produce proportionally greater GH output and increases the risk of transient cortisol and prolactin elevation. Timing matters more than dose escalation — administering MK-677 60–90 minutes before sleep onset synchronizes peak plasma concentration with the natural nocturnal GH pulse window, maximizing efficacy without requiring doses above the standard 25mg ceiling used in human trials.

MK-677 does not suppress endogenous GH secretion, so tolerance to its GH-elevating effect does not develop over standard 8–12 week research cycles — long-term studies show sustained IGF-1 elevation without dose escalation. DSIP similarly shows no tolerance development to its sleep architecture effects in trials lasting up to 16 weeks, though subjective sleep quality ratings sometimes decline as subjects habituate to improved sleep and rate it as baseline. The stack does not require mandatory cycling for receptor desensitization reasons, but some protocols include a one-week washout every 8–12 weeks to re-baseline sleep and endocrine metrics for cleaner data comparison. Neither compound produces withdrawal effects or rebound sleep disruption when discontinued.

DSIP's effects on sleep architecture appear within the first administration — polysomnography shows increased slow-wave sleep duration and reduced sleep latency on night one. MK-677's GH elevation occurs within 24–48 hours of the first dose, but downstream metabolic markers (IGF-1 increase, nitrogen retention, body composition changes) require 10–14 days to stabilize as the endocrine system adjusts to elevated GH pulsatility. Research models measuring 24-hour GH AUC show peak synergy between MK-677 and DSIP by week two, when MK-677's cortisol-elevating effect resolves and DSIP's cortisol-buffering action stabilizes the HPA axis. Functional outcomes like improved recovery markers or altered body composition typically manifest after four weeks of consistent dosing.

The primary side effect is increased appetite driven by MK-677's ghrelin receptor agonism — approximately 60% of subjects report pronounced hunger within the first two weeks, which can interfere with sleep onset if MK-677 is dosed too close to bedtime. Water retention occurs in 30–40% of models during the first 10–14 days due to transient aldosterone and cortisol elevation, resolving as the HPA axis adapts. DSIP produces minimal standalone side effects, though some subjects report mild morning grogginess if dosed above 500mcg subcutaneously. The stack does not produce the joint pain, carpal tunnel, or insulin resistance associated with exogenous GH abuse because MK-677 preserves physiological GH pulsatility. Cortisol elevation from MK-677 is typically offset by DSIP's stress-buffering effects, but models with pre-existing HPA dysregulation may see prolonged cortisol increase past week two.

No — MK-677 amplifies endogenous GH secretion but cannot match the supraphysiological plasma GH concentrations achieved with exogenous GH injections (typically 5–10 IU daily in research or clinical contexts). MK-677 at 25mg produces GH levels roughly equivalent to 1–2 IU exogenous GH, which is sufficient for metabolic optimization but insufficient for therapeutic applications requiring pharmacological GH doses (growth hormone deficiency treatment, severe muscle wasting). The advantage of MK-677 over exogenous GH is preservation of pulsatile secretion and avoidance of negative feedback suppression — exogenous GH shuts down endogenous production entirely, creating dependency. The MK-677 + DSIP stack is best understood as a physiological optimization tool, not a replacement for medical GH therapy.

Subcutaneous DSIP injection achieves approximately 80% bioavailability with slower but more sustained CNS penetration, making it the preferred route for dose-precision research requiring exact peptide concentrations. Intranasal DSIP bypasses first-pass metabolism and crosses the blood-brain barrier faster via olfactory transport, reaching peak CNS activity 10–15 minutes post-administration versus 20–30 minutes for subcutaneous. However, intranasal bioavailability is lower (40–60%) due to mucosal absorption variability and nasal drainage loss. Research protocols prioritizing rapid sleep onset favor intranasal delivery; those requiring reproducible dosing across subjects use subcutaneous. Both routes produce equivalent sleep architecture modulation when adjusted for bioavailability differences.

MK-677 monotherapy produces transient insulin resistance in the first two weeks of administration due to elevated GH and cortisol, but this effect typically resolves as the endocrine system adapts — long-term studies show neutral to slightly improved insulin sensitivity after 12 weeks at 25mg daily. DSIP does not independently affect glucose metabolism but may indirectly support insulin sensitivity by reducing cortisol, which antagonizes insulin signaling. The stack does not produce the chronic insulin resistance seen with exogenous GH abuse because MK-677 preserves pulsatile GH secretion rather than creating sustained supraphysiological levels. Research models with pre-existing metabolic dysfunction (prediabetes, metabolic syndrome) should monitor fasting glucose and HbA1c during the first month, but healthy models show minimal glucose disruption.

Key markers include IGF-1 (primary endpoint for integrated GH exposure), fasting glucose and insulin (to detect transient insulin resistance), cortisol (to track HPA axis adaptation), and prolactin (MK-677 transiently elevates prolactin in some subjects). For comprehensive GH assessment, 24-hour GH area-under-curve requires serial blood draws every 20–30 minutes, but IGF-1 serves as a practical proxy with a 12–16 hour half-life that smooths pulse variability. Thyroid function (TSH, free T3, free T4) should be monitored because elevated GH can increase peripheral T4-to-T3 conversion. Lipid panels and liver enzymes remain stable in most models but warrant baseline and endpoint checks in protocols lasting beyond 12 weeks. Sleep architecture metrics require polysomnography or research-grade actigraphy — consumer wearables lack the delta-wave classification accuracy needed to validate DSIP's SWS-extending effects.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA